Trimedyne Receives $6.5 Million Payment

Business Wire, Dec 7, 1998

IRVINE, Calif.--(BUSINESS WIRE)--Dec. 7, 1998--Trimedyne Inc. (Nasdaq/NMS:TMED) Monday announced it received the $6.5 million payment from C.R. Bard Inc. due under the settlement agreement reached in late November.

As a result of this payment, Trimedyne's stockholders' equity has increased to approximately $16,870,000 or $1.55 per share as of this date (unaudited).

Receipt of these funds will enable Trimedyne to complete the Angiogenic Injection and Laser Heart Revascularization System being developed by its 90 percent owned subsidiary, Cardiodyne Inc., as well as continuing Trimedyne's development of new products in urology, cosmetic surgery, neurosurgery and gynecology.

Trimedyne is a leading manufacturer of surgical lasers located in Irvine. Trimedyne manufactures a family of Holmium and Nd:YAG lasers for use in urology, orthopedics, ENT surgery, gynecology and general surgery to treat a variety of diseases and medical conditions.

"Safe Harbor" Statement Under the Private Securities Litigation Reform Act: With the exception of any historical information contained in this release, the matters described herein contain forward-looking statements that involve risk and uncertainties that may, individually or mutually, impact the matters herein described. Such risks may be outside the control of the company, and may be detailed from time to time in the company's periodic SEC reports.